National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings, 26486-26487 [2018-12175]
Download as PDF
sradovich on DSK3GMQ082PROD with NOTICES
26486
Federal Register / Vol. 83, No. 110 / Thursday, June 7, 2018 / Notices
industry and investment industry in
order to increase innovation and
investment in the healthcare sector?
2. How the workgroup should be
convened and structured, including
what subsectors of the healthcare
economy should be invited to
participate, and the most effective size.
How should the agency structure
meetings or other engagements in order
to best facilitate the exchange of
information and the presentation of
attendees’ individual perspectives? The
Department seeks comment on how
suitable attendees should be identified
and selected to attend and engage in an
exchange of ideas about the
Department’s goals of increasing
innovation and investment in the
healthcare sector.
3. HHS also seeks comment more
broadly on opportunities for increased
engagement and dialogue between HHS
and those focused on innovating and
investing in the healthcare industry,
including alternatives to the workgroup
structure discussed in this request for
information. The Department is
interested in comments that propose
alternatives for developing a durable
and consistent approach to increase
innovation and investment in the
healthcare sector to improve the public
health and wellbeing of Americans.
This is a request for information only.
Respondents are encouraged to provide
complete but concise responses to any
or all of the questions outlined above.
This request for information is issued
solely for information and planning
purposes; it does not constitute a notice
of proposed rulemaking or request for
proposals, applications, proposal
abstracts, or quotations, nor does it
suggest that the Department will
undertake any particular action in
response to comments. This request for
information does not commit the United
States Government (‘‘Government’’) to
contract for any supplies or services or
make a grant award. Further, HHS is not
seeking proposals through this request
for information and will not accept
unsolicited proposals. Respondents are
advised that the Government will not
pay for any information or
administrative costs incurred in
response to this request for information;
all costs associated with responding to
this request for information will be
solely at the interested party’s expense.
Not responding to this request for
information does not preclude
participation in any future rulemaking
or procurement, if conducted. It is the
responsibility of the potential
responders to monitor this request for
information announcement for
additional information pertaining to this
VerDate Sep<11>2014
17:19 Jun 06, 2018
Jkt 244001
request. We also note that HHS will not
respond to questions about the policy
issues raised in this request for
information. HHS may or may not
choose to contact individual responders.
Such communications would only serve
to further clarify written responses.
Contractor support personnel may be
used to review the responses submitted
under this request for information.
Responses to this notice are not offers
and cannot be accepted by the
Government to form a binding contract
or issue a grant. Information obtained in
response to this request for information
may be used by the Government for
program planning on a non-attribution
basis. Respondents should not include
any information that might be
considered proprietary or confidential.
This request for information should not
be construed as a commitment or
authorization to incur cost for which
reimbursement would be required or
sought. All submissions become
Government property and will not be
returned. HHS may publicly post the
comments received, or a summary
thereof. While responses to this request
for information do not bind HHS to any
further actions related to the response,
all comments may be posted online on
https://www.regulations.gov.
III. Collection of Information
This document does not impose
information collection requirements;
that is, reporting, recordkeeping or
third-party disclosure requirements.
This request for information constitutes
a general solicitation of comments. In
accordance with the implementing
regulations of the Paperwork Reduction
Act of 1995 (PRA) at 5 CFR 1320.3(h)(4),
information subject to the PRA does not
generally include ‘‘facts or opinions
submitted in response to general
solicitations of comments from the
public, published in the Federal
Register or other publications,
regardless of the form or format thereof,
provided that no person is required to
supply specific information pertaining
to the commenter, other than that
necessary for self-identification, as a
condition of the agency’s full
consideration of the comment.’’
Consequently, this document need not
be reviewed by the Office of
Management and Budget under the
authority of the PRA (44 U.S.C. 3501 et
seq.).
Authority: 42 U.S.C. 3501.
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Dated: June 1, 2018.
Eric D. Hargan,
Deputy Secretary, Department of Health and
Human Services.
[FR Doc. 2018–12234 Filed 6–6–18; 8:45 am]
BILLING CODE 4150–03–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Arthritis and
Musculoskeletal and Skin Diseases Initial
Review Group; Arthritis and Musculoskeletal
and Skin Diseases Special Grants Review
Committee.
Date: June 13–14, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites, Chevy Chase
Pavilion, 4300 Military Rd. NW, Washington,
DC 20015.
Contact Person: Helen Lin, Ph.D.,
Scientific Review Officer, NIH/NIAMS/RB,
6701 Democracy Blvd., Suite 800, Plaza One,
Bethesda, MD 20817, 301–594–4952, linh1@
mail.nih.gov.
Name of Committee: Arthritis and
Musculoskeletal and Skin Diseases Initial
Review Group; Arthritis and Musculoskeletal
and Skin Diseases Clinical Trials Review
Committee.
Date: June 19, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, 1 Bethesda
Metro Center, Bethesda, MD 20814.
Contact Person: Nakia C Brown, Ph.D.,
Scientific Review Officer, 6701 Democracy
Blvd., RM 816, Bethesda, MD 20892, 301–
827–4905, brownnac@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
E:\FR\FM\07JNN1.SGM
07JNN1
Federal Register / Vol. 83, No. 110 / Thursday, June 7, 2018 / Notices
Dated: June 1, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–12175 Filed 6–6–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: The Development of an
Anti-BCMA Immunotoxin for the
Treatment of Human Cancer
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this notice to BEORO
Therapeutics, GmbH. (‘‘Beoro’’) located
in Seefeld, Germany.
DATES: Only written comments and/or
complete applications for a license
which are received by the National
Cancer Institute’s Technology Transfer
Center on or before June 22, 2018 will
be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: David A. Lambertson, Ph.D.,
Senior Technology Transfer Manager,
NCI Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702 Telephone: (240)–276–5530;
Facsimile: (240)–276–5504 Email:
david.lambertson@nih.gov.
SUPPLEMENTARY INFORMATION:
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
Intellectual Property
The following represents the
intellectual property to be licensed
under the prospective agreement:
U.S. Patent Application 62/255,255
(HHS reference E–010–2016–0–US–01),
U.S. Patent Application 62/257,493
(HHS reference E–010–2016–1–US–01),
and PCT Patent Application PCT/
US2016/061320 (HHS reference E–010–
2016–2–PCT–01);
U.S. Patent Application 61/887,418
(HHS reference E–771–2013–0–US–01),
U.S. Patent Application 61/908,464
VerDate Sep<11>2014
17:19 Jun 06, 2018
Jkt 244001
(HHS reference E–771–2013–1–US–01),
U.S. Patent Application 61/982,051
(HHS reference E–771–2013–2–US–01),
U.S. Patent Application 61/052,665
(HHS reference E–771–2013–3–US–01),
PCT Application PCT/US2014/058941
(HHS reference E–771–2013–4–PCT–
01), U.S. Patent 9,388,222 (HHS
reference E–771–2013–4–US–02),
Australian Patent Application
2014329437 (HHS reference E–771–
2013–4–AU–08), Canadian Patent
Application 2926215 (HHS reference E–
771–2013–4–CA–09), Chinese Patent
Application 201480062185.7 (HHS
Reference E–771–2013–4–CN–10),
European Patent Application
14789449.7 (HHS reference E–771–
2013–4–EP–11), Indian Patent
Application 201647015226 (HHS
reference E–771–2013–4–IN–12),
Russian Patent Application 2016114406
(HHS reference E–771–2013–4–RU–13),
Japanese Patent Application (HHS
reference E–771–2013–4–JP–14), and
U.S. Patent Application 15/191,392
(HHS reference E–771–2013–4–US–15);
U.S. Patent Application 61/535,668
(HHS reference E–263–2011–0–US–01),
PCT Application PCT/US2012/055034
(HHS reference E–263–2011–0–PCT–
02), Australian Patent 2012308591 (HHS
reference E–263–2011–0–AU–03),
Canadian Patent Application 2846608
(HHS reference E–263–2011–0–CA–04),
European Patent 2755993 (HHS
reference E–263–2011–0–EP–05), U.S.
Patent 9,206,240 (HHS reference E–263–
2011–0–US–06), Hong Kong Patent
Application 14111650.2 (HHS reference
E–263–2011–0–HK–07), U.S. Patent
9,657,066 (HHS reference E–263–2011–
0–US–08), U.S. Patent Application 15/
488,898 (HHS reference E–263–2011–0–
US–09) and European Patent
Application 14/927,645 (HHS reference
E–263–2011–0–EP–18);
U.S. Patent Application 61/495,085
(HHS reference E–174–2011–0–US–01),
PCT Application PCT/US2012/041234
(HHS reference E–174–2011–0–PCT–
02), Australian Patent 2012268013 (HHS
reference E–174–2011–0–AU–03),
Brazilian Patent Application
112013031262–9 (HHS reference E–
174–2011–0–BR–04), Canadian Patent
Application 2838013 (HHS reference E–
174–2011–0–CA–05), Chinese Patent
Application 201280039071.1 (HHS
reference E–174–2011–0–CN–06),
European Patent 2718308 (HHS
reference E–174–2011–0–EP–07) as
validated in Germany, Spain, France,
the United Kingdom, and Italy, Hong
Kong Patent Application 14105911.9
(HHS reference E–174–2011–0–HK–08),
Japanese Patent 6100764 (HHS reference
E–174–2011–0–JP–09), South Korean
Patent Application 2013–7032402 (HHS
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
26487
reference E–174–2011–0–KR–10),
Mexican Patent Application MX/a/
2013/014388 (HHS reference E–174–
2011–0–MX–11), Russian Patent
2627216 (HHS reference E–174–2011–
0–RU–12), U.S. Patent 9,346,859 (HHS
reference E–174–2011–0–US–13), Hong
Kong Patent Application 14106689.7
(HHS reference E–174–2011–0–HK–14),
U.S. Patent 9,765,123 (HHS reference E–
174–2011–0–US–15), Australian Patent
Application 2017200541 (HHS reference
E–174–2011–0–AU–16), European
Patent Application 17163568.3 (HHS
reference E–174–2011–0–EP–17),
Japanese Patent Application 2017–
031283 (HHS reference E–174–2011–0–
JP–18), and U.S. Patent Application 15/
693,705 (HHS reference E–174–2011/0–
US–24);
U.S. Patent Application 61/241,620
(HHS reference E–269–2009–0–US–01),
PCT Application PCT/US2010/048504
(HHS reference E–269–2009–0–PCT–
02), Australian Patent 2010292069 (HHS
reference E–269–2009–0–AU–03),
Canadian Patent 2773665 (HHS
reference E–269–2009–0–CA–04),
Chinese Patent 201080049559.3 (HHS
reference E–269–2009–0–CN–05),
European Patent 2475398 (HHS
reference E–269–2009–0–EP–06), as
validated in France, Germany, Italy,
Spain and the United Kingdom, Indian
Patent Application 3197/CHENP/2012
(HHS reference E–269–2009–0–IN–07),
Japanese Patent 5795765 (HHS reference
E–269–2009–0–JP–08), Russian Patent
Application 2012114005 (HHS reference
E–269–2009–0–RU–09), and U.S. Patent
8,936,792 (HHS reference E–269–2009–
0–US–10);
U.S. Patent Application 60/969,929
(HHS reference E–292–2007–0–US–01),
PCT Application PCT/US2008/075296
(HHS reference E–292–2007–0–PCT–
02), Australian Patent 2008296194 (HHS
reference E–292–2007–0–AU–03),
Canadian Patent 2698357 (HHS
reference E–292–2007–0–CA–04),
European Patent 2197903 (HHS
reference E–292–2007–0–EP–05) as
validated in Austria, Belgium, Bulgaria,
Switzerland, Cyprus, Germany,
Denmark, Estonia, Spain, Finland,
France, the United Kingdom, Greece,
Croatia, Hungary, Ireland, Italy,
Lithuania, Luxembourg, Latvia, Monaco,
Malta, the Netherlands, Norway,
Poland, Portugal, Romania, Slovenia,
Slovakia, and Turkey, U.S. Patent
8,871,906 (HHS reference E–292–2007–
0–US–06), European Patent 2570425
(HHS reference E–292–2007–0–EP–07)
as validated in France, Germany, the
United Kingdom, Italy and Spain, and
Hong Kong Patent Application
13106628.2 (HHS reference E–292–
2007–0–HK–08);
E:\FR\FM\07JNN1.SGM
07JNN1
Agencies
[Federal Register Volume 83, Number 110 (Thursday, June 7, 2018)]
[Notices]
[Pages 26486-26487]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-12175]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Arthritis and Musculoskeletal and Skin
Diseases Initial Review Group; Arthritis and Musculoskeletal and
Skin Diseases Special Grants Review Committee.
Date: June 13-14, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites, Chevy Chase Pavilion, 4300 Military Rd.
NW, Washington, DC 20015.
Contact Person: Helen Lin, Ph.D., Scientific Review Officer,
NIH/NIAMS/RB, 6701 Democracy Blvd., Suite 800, Plaza One, Bethesda,
MD 20817, 301-594-4952, [email protected].
Name of Committee: Arthritis and Musculoskeletal and Skin
Diseases Initial Review Group; Arthritis and Musculoskeletal and
Skin Diseases Clinical Trials Review Committee.
Date: June 19, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hyatt Regency Bethesda, 1 Bethesda Metro Center,
Bethesda, MD 20814.
Contact Person: Nakia C Brown, Ph.D., Scientific Review Officer,
6701 Democracy Blvd., RM 816, Bethesda, MD 20892, 301-827-4905,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.846,
Arthritis, Musculoskeletal and Skin Diseases Research, National
Institutes of Health, HHS)
[[Page 26487]]
Dated: June 1, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-12175 Filed 6-6-18; 8:45 am]
BILLING CODE 4140-01-P